Castrop Florian, Haslinger Bernhard, Hemmer Bernhard, Buck Dorothea
Department of Neurology, Technische Universität München, Munich, Germany.
Neuropsychiatr Dis Treat. 2013;9:1339-49. doi: 10.2147/NDT.S33949. Epub 2013 Sep 16.
Multiple sclerosis (MS) is a common neurological disease with increasing incidence and prevalence. Onset of disease is most frequently in young adulthood when productivity is usually highest; it is of chronic nature and, in the majority of patients, it will result in accumulation of disability. Due to loss of productivity in patients and caregivers as well as high expenses for medical treatment, MS is considered a disease with high economic burden for patients and society. Several drugs have been approved for treatment of MS. While treatment ameliorates the course of the disease, it is very costly; therefore, pharmacoeconomics, evaluating costs and effects of disease-modifying treatment in MS, has become an important issue. Here, we review the economic impact and treatment strategies of MS and discuss recent studies on pharmacoeconomics of early treatment with interferon beta.
多发性硬化症（MS）是一种发病率和患病率不断上升的常见神经系统疾病。疾病最常发生在青壮年时期，而这一时期通常生产力最高；它具有慢性性质，在大多数患者中，会导致残疾累积。由于患者和护理人员生产力的丧失以及高昂的医疗费用，MS被认为是一种给患者和社会带来高经济负担的疾病。已有几种药物被批准用于治疗MS。虽然治疗可改善疾病进程，但费用非常高昂；因此，评估MS疾病修饰治疗的成本和效果的药物经济学已成为一个重要问题。在此，我们综述MS的经济影响和治疗策略，并讨论近期关于干扰素β早期治疗药物经济学的研究。
